The UK's Association of Investment Companies says that a recent survey of fund managers shows that many of them believe the life sciences sector is under-valued.
The London-based organization, which represents the interests of the investment trust industry, noted that drugmakers have held up well over the last year of economic uncertainty, posting a gain of 10%, while other industries have suffered losses. Over the last three, five and 10 years the sector is down 10%, up 14% and up 168%, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze